CRISPR

The CRISPR-Cas9 gene editing technology was developed by Jennifer Doudna and Emmanuelle Charpentier, who were awarded the 2020 Nobel Prize in Chemistry for this work.

Claude agents discovered an abnormal repetitive DNA sequence with a structure highly similar to CRISPR; human scientists verified and confirmed it as a real biological system not previously defined, naming it ART.

A single CRISPR edit is easy; what is difficult is modifying hundreds or thousands of sites simultaneously without triggering off-target effects and genomic instability, which is also an important reason why AI was introduced to optimize editing strategies.

In de-extinction scenarios, the value of CRISPR lies in precise rewriting: researchers use the genome of a closely related species (such as the Asian elephant) as the chassis and edit in, one by one, the key difference sites inferred from the residual DNA of the extinct species (such as the woolly mammoth).

Colossal Biosciences was founded by Ben Lamm and George Church, with the core goal of using CRISPR gene editing, stem cell technology and synthetic biology methods to bring extinct species back to Earth.

In the de-extinction pathway, CRISPR is responsible for changing, synthetic biology is responsible for building and regulating, and AI is responsible for searching for feasible solutions among the vast space of possible options; de-extinction is seen as a systems engineering effort highly dependent on interdisciplinary infrastructure.

The value of many important scientific discoveries (such as the theory of relativity and CRISPR gene-editing technology) takes decades to become apparent and is difficult to accurately assess at the time of their emergence

The scientists associated with CRISPR received the Nobel Prize in Chemistry in 2020.

Anthropic announced that Claude found a clue to a new defense system with repetitive sequences in vast DNA data, structurally similar to CRISPR-related mechanisms, though its specific function remains unclear.

The specific function of ART is currently unclear, and there is no evidence that it can be used for gene editing in the same way as CRISPR.

The few known systems with CRISPR-like characteristics are all capable of cutting, copying, and pasting DNA.

The enzyme system located by Claude has a long repetitive DNA array immediately adjacent to its gene, an arrangement that is the hallmark organizational form of CRISPR systems.

CRISPR was first incidentally observed in bacterial genomes in 1987, and its immune function was not elucidated until 2007.

The core logic of the CRISPR system is that guide RNA is responsible for targeting the DNA sequence, while the Cas protein is responsible for executing the cut.

Multiple CRISPR-based therapies have been approved and brought to market for treating genetic diseases such as sickle cell disease.

Currently known CRISPR systems are classified into two classes (Class 1 and Class 2) comprising six subtypes in total, with each subtype corresponding to a different family of effector proteins.

Proteins such as Cas9, Cas12, and Cas13 were discovered through research into CRISPR systems.

CRISPR is an adaptive immune system used by bacteria and archaea to defend against viruses.

Validation of CRISPR-related enzyme systems also requires demonstrating whether they can bind guide RNA, whether they can cleave specific targets, and their cleavage specificity.

In 1993, researchers noticed an unusual repeat-spacer structure in the E. coli genome, but its functional significance was not gradually elucidated until the 2000s.